FDA & Women’s Health: The FDA granted priority review for elinzanetant (Lynqwet) for moderate-to-severe VMS in HR+ breast cancer patients on endocrine therapy, after OASIS-4 Phase III results showed significant VMS frequency reductions at weeks 4 and 12 (with somnolence, fatigue, and diarrhea more common than placebo). Obesity Drug Race: A new analysis looks beyond semaglutide and tirzepatide, highlighting how the next obesity medicines may reshape care—but also stressing the need for head-to-head data, safety clarity, and indication-specific trials. Cancer Care Updates: Proton therapy again faces a setback—proton does not improve survival in advanced HCC in a Phase III trial—while other studies report progress across oncology, including durable responses with CD47-targeted evorpacept in HER2+ gastric cancer and new filings for MET+ NSCLC. Healthcare Access & Costs: CareSource and Molina will exit Ohio’s ACA Marketplace in 2027, affecting about 54,000 people, while Blue Cross Blue Shield Association research links AI-assisted hospital coding to roughly $1B in added insurer costs without added care. Workforce & Systems: HL7 launched “Break the Code,” a free FHIR workforce program aimed at filling a global interoperability talent gap. Community Health: A $300K grant expands mobile food access in Suffolk, Va., and Dartmouth Health announced a new at-home program to tackle rural care barriers after a $20M gift. Policy & Coverage: HealthPartners and Essentia Health announced a Minnesota merger, with unions warning about jobs and costs.